Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 2Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Esophageal Squamous Cell Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Vomiting 1Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Nausea 1Lung Neoplasms 1Klatskin Tumor 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 17pembrolizumab 16Cisplatin 14enfortumab vedotin 7avelumab 7Nivolumab 6Docetaxel 6atezolizumab 5Paclitaxel 5Cystectomy 5sacituzumab govitecan 4durvalumab 4Mitomycin 4Cystoscopy 4Carboplatin 4vofatamab 3tremelimumab 3Radiotherapy 3Magnetic Resonance Spectroscopy 3vinflunine 2tisotumab vedotin 2poly ICLC 2cemiplimab 2aldesleukin 2Transurethral Resection of Bladder 2Radiotherapy, Intensity-Modulated 2Ipilimumab 2Interleukin-2 2Immunoglobulin G 2Clinical Trials, Phase II as Topic 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Urinary Bladder Neoplasms × Neoadjuvant Therapy × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔